Encepheal Therapeutics
Encepheal Therapeutics, based in Winston-Salem, NC, was a healthcare company specializing in developing small molecule therapeutics for treating substance abuse, particularly stimulants like cocaine and methamphetamine.
Company Overview
Encepheal Therapeutics is a healthcare company based in Winston-Salem, NC, USA. With a small team of three, Encepheal is dedicated to developing medications to treat substance abuse. The company was launched in April 2019 and was part of Y Combinator's S19 batch. Although currently inactive, Encepheal has partnered with the National Institutes of Health and shown significant potential in the therapeutics sub-industry.
Products
Encepheal Therapeutics' first product is a small molecule therapeutic aimed at treating addiction to stimulants such as cocaine and methamphetamine. This innovative product employs small molecule technology to function as atypical inhibitors of the dopamine transporter. Research indicates that these new allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models and are effective at curbing cocaine addiction.
Industry and Partnerships
Encepheal Therapeutics operates within the healthcare industry, specifically focusing on therapeutics for substance abuse. The company has partnered with the National Institutes of Health to advance its research and development efforts. Additionally, Encepheal has expertise in acquiring SBIR/STTR grants, highlighting its capability in grant writing and funding procurement. The company is keen on establishing further connections within the biotech and pharmaceutical industries.
Locations and Regions
Encepheal Therapeutics is located in Winston-Salem, NC, USA. While its operations are based in the United States, its reach extends to broader regions including America and Canada. Being part of these regions allows the company to tap into extensive markets and potential research collaborations.
History and Y Combinator
Launched in April 2019, Encepheal Therapeutics was a participant in Y Combinator's S19 batch. As part of this prestigious startup accelerator, the company gained valuable exposure and resources to advance its innovative solutions for substance abuse treatment. Despite its current inactive status, Encepheal's history with Y Combinator remains a notable aspect of its development timeline.